FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding ...

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal ...

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous ...

Advancements in cancer care focus on precise detection of measurable residual disease, enhancing monitoring and relapse ...

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a ...

The investigational treatment DZD8586 elicited encouraging antitumor activity with manageable toxicity in heavily pretreated ...

Jeremy S. Abramson, MD, discusses the significant 2-year follow-up results from the phase 3 STARGLO trial in DLBCL.

Jacob E. Berchuck, MD, discusses research on plasma epigenomic profiling in metastatic castration-resistant prostate cancer.

Jamie Jacobs, PhD, provides background on a digital intervention for caregivers of patients undergoing bone marrow transplant.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...